Effects of dasatinib on xenograft lung tumour models with YES1 overexpression

AACR 2018

14 - 18 Apr 2018

Published: 25 Apr 2018

Rating:

Save

Dr Irati Garmendia - University of Navarra, Pamplona, Spain

Dr Garmendia speaks with ecancer at AACR 2018 about patient derived xenografts (PDX) of lung tumours with high levels of YES1.

She describes how dasatinib significantly reduced tumour growth in YES1 models, and its suitability as a companion marker for treatment selection in lung cancer.

My poster is about lung cancer. We are studying YES1 amplification in lung cancer. We have used PDX mouse models to treat them with dasatinib which is a YES1 inhibitor. What we have seen is that dasatinib inhibits tumour growth in those PDX harbouring tumours with YES1 amplification and high expression but not on those mice with low YES1 expression.

What are the implications for the future from this work?

It’s very interesting because dasatinib has been studied in a lot of clinical trials but there is not any marker telling us which patients can benefit from dasatinib treatment. So we propose that YES1 can be a marker so those patients harbouring YES1 amplification can benefit from dasatinib.

What were the main challenges involved in this work?

Working with mice is really hard work. Of course we have treated them with dasatinib daily so it’s really hard work but we have obtained very good results so I think that it’s fine.